| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA433: Apremilast for treating active psoriatic arthritis (replaced TA372) |
|
Medicine details |
|
| Medicine name | apremilast (Otezla®) |
| Formulation | 10 mg, 20 mg, 30 mg film-coated tablet |
| Reference number | 1712 |
| Indication | Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy |
| Company | Celgene Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/01/2015 |
| NICE guidance | TA433: Apremilast for treating active psoriatic arthritis (replaced TA372) |